Triad Wealth Partners’s AbbVie ABBV Stock Holding History

Triad Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.58M	Buy	18,700 +8,921	+91%	+$1.92M	0.27%	67
2026 Q1	$2.13M	Buy	9,779 +891	+10%	+$198K	0.17%	97
2025 Q4	$2.03M	Buy	8,888 +1,544	+21%	+$352K	0.19%	86
2025 Q3	$1.7M	Buy	7,344 +2,122	+41%	+$432K	0.22%	76
2025 Q2	$969K	Sell	5,222 -9	-0.2%	-$1.67K	0.2%	92
2025 Q1	$1.1M	Buy	5,231 +719	+16%	+$140K	0.34%	52
2024 Q4	$802K	Buy	+4,512	New	+$830K	0.29%	60
2024 Q3	–	Sell	-3,139	Closed	-$538K	–	52
2024 Q2	$538K	Buy	3,139 +402	+15%	+$66.6K	0.28%	35
2024 Q1	$498K	Buy	+2,737	New	+$472K	0.38%	29

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Triad Wealth Partners's ABBV Position: Q2 2026 in Review

Triad Wealth Partners increased its AbbVie (ABBV) stake by 91% in Q2 2026, buying an estimated $1.92M and bringing the position to 18,700 shares worth $4.58M. The position accounts for 0.27% of the portfolio, ranked #67.

Triad Wealth Partners first reported a position in ABBV in Q1 2024 and has held it in 9 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Triad Wealth Partners held 18,700 shares of AbbVie worth $4.58M as of Q2 2026.
Triad Wealth Partners bought 8,921 AbbVie shares in Q2 2026, an estimated $1.92M.
AbbVie made up 0.27% of Triad Wealth Partners's portfolio in Q2 2026, its #67 holding.
Triad Wealth Partners first reported a position in AbbVie in Q1 2024 and has held it in 9 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Triad Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.